Results 271 to 280 of about 28,819,884 (406)

Early CD4+ T cell proliferation and chronic T cell engagement impact myeloma outcomes following T cell engager therapy. [PDF]

J Clin Invest
Duffy AM, Goenka A, Azeem MI, Taz A, Potdar SV, Scott SA, Marin E, Kaufman JL, Hofmeister CC, Joseph NS, Gupta VA, Lonial S, Nooka AK, Dhodapkar MV, Dhodapkar KM.   +14 more
europepmc   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

Proteasome: Role in T Cell Function Regulation. [PDF]

Int J Biol Sci
Tang D, Wu X, Lei JH, Qiao Y, Deng CX.
europepmc   +1 more source

In vitro models of cancer‐associated fibroblast heterogeneity uncover subtype‐specific effects of CRISPR perturbations

Molecular Oncology, EarlyView.
Development of therapies targeting cancer‐associated fibroblasts (CAFs) necessitates preclinical model systems that faithfully represent CAF–tumor biology. We established an in vitro coculture system of patient‐derived pancreatic CAFs and tumor cell lines and demonstrated its recapitulation of primary CAF–tumor biology with single‐cell transcriptomics ...
Elysia Saputra, Shamsudheen Karuthedath Vellarikkal, Lixia Li, Hong Sun, Khoa Nguyen, Amber Montano, Suchitra Natarajan, Federica Piccioni, Alex Michael Tamburino, Xin Yu, Aleksandra Katarzyna Olow   +10 more
wiley   +1 more source

Acquisition of an immunosuppressive microenvironment after anti-CD19 CAR T-cell therapy is associated with T-cell dysfunction and resistance. [PDF]

J Immunother Cancer
Ponzo M, Drufuca L, Buracchi C, Sindoni MM, Nucera S, Bugarin C, Bason R, Rossetti G, Bonnal R, Meli C, Rambaldi B, Lussana F, Ferrari S, Moretti A, Dastoli G, Risca G, Pellegrino C, Manz MG, Galimberti S, Rambaldi A, Gaipa G, Biondi A, Pagani M, Magnani CF.   +23 more
europepmc   +1 more source

Effect of chemotherapy on passenger mutations in metastatic colorectal cancer

Molecular Oncology, EarlyView.
Changes in passenger mutation load and predicted immunotherapy response after chemotherapy treatment. Tumor cells rich with passenger mutations have increased sensitivity to chemotherapy. Correlation of passenger mutations with neoantigen load suggests highly mutated clones promote a more effective response to immunotherapy, and therefore, first‐line ...
Marium T. Siddiqui, Matthew A. Cottam, Muhammad Bilal Mirza, Keeli B. Lewis, Kristen K. Ciombor, Mary Kay Washington, Kamran Idrees   +6 more
wiley   +1 more source

The Pleiotropic Roles of Cytokines in Chimeric Antigen Receptor T-cell Therapy. [PDF]

Cancer Immunol Res
Stewart CM, Siegler EL, Kenderian SS.
europepmc   +1 more source

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

Science Translational Medicine, 2014
M. Davila, I. Rivière, Xiuyan Wang, S. Bartido, Jae H. Park, K. Curran, S. Chung, J. Stefanski, Oriana Bórquez-Ojeda, M. Olszewska, Jinrong Qu, Teresa Wasielewska, Q. He, Mitsú J. Fink, Himaly Shinglot, M. Youssif, M. Satter, Yongzeng Wang, James Hosey, Hilda Quintanilla, E. Halton, Y. Bernal, Diana C. G. Bouhassira, M. Arcila, M. Gonen, G. Roboz, P. Maslak, D. Douer, M. Frattini, S. Giralt, M. Sadelain, R. Brentjens   +31 more
semanticscholar   +1 more source

Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells

Molecular Oncology, EarlyView.
Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Juhyeon Son, Lily L. Remsing Rix, Bin Fang, Eric A. Welsh, Nicole V. Bremer, Valentina Foglizzo, Paola Roa, Nickole Sigcha‐Coello, Yi Liao, Eric B. Haura, Alexander Drilon, John M. Koomen, Emiliano Cocco, Uwe Rix   +13 more
wiley   +1 more source

OGG1 activation improves T cell resilience to oxidative stress after allo-SCT and T cell engager exposure. [PDF]

Leukemia
Saul D, Lischer C, Bruns H, Ziegler N, Kannt A, Michel M, Mougiakakos D.   +6 more
europepmc   +1 more source